3rd Jun 2020 10:36
(Alliance News) - Indivior PLC on Wednesday said it is considering its appeal options against a final ruling by the US patent board in a case relating to generic production of the company's blockbuster opoid addiction treatment drug Suboxone by Indian pharmaceutical company Dr. Reddy's Laboratories.
The Patent Trial & Appeal Board of the US Patent & Trademark Office has ruled that some parts of Indivior's patent for Suboxone are "unpatentable"
"Today, the Patent Trial & Appeal Board held that Dr. Reddy's Laboratories demonstrated by a preponderance of the evidence that claims 1-5, 7, and 9-14 of the '454 patent are unpatentable, but have not demonstrated by a preponderance of the evidence that claim 8 of the '454 patent is unpatentable. Claim 6 was not challenged and therefore is not addressed by the PTAB's opinion," Indivior said.
Dr. Reddy's in November 2018 filed two petitions against Indivior's Suboxone patent so it could launch a cheaper generic version of the drug.
The US patent office denied institution of one of the inter partes to review petition, but granted Dr. Reddy's for the second IPR petition
Shares in Indivior were trading 1.5% lower on Wednesday in London at 63.05 pence each.
By Tapan Panchal; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Indivior